Stock TRX TISSUE REGENIX GROUP PLC
Add to a list
To use this feature you must be a member
Log inSign up

Financials Tissue Regenix Group plc

Equities

TRX

GB00BNTXR104

Advanced Medical Equipment & Technology

Delayed London S.E.
Other stock markets
 10:57:06 27/06/2024 BST 		5-day change 1st Jan Change
64.6 GBX -1.37% Intraday chart for Tissue Regenix Group plc -0.62% +24.23%
06-14 Tissue Regenix purchases Texas facility to generate cost savings AN
06-14 Tissue Regenix Buys Leased Property in Texas MT

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025
Capitalization 1 11.56 37.89 37.54 39.66 36.61 46.66 -
Enterprise Value (EV) 1 11.46 31.13 35.07 39.91 37.66 49.28 50.5
P/E ratio -1.67 x -2.45 x -9.91 x -17.1 x -27.2 x -390 x 157 x
Yield - - - - - - -
Capitalization / Revenue 0.89 x 2.95 x 2.48 x 1.99 x 1.58 x 1.72 x 1.5 x
EV / Revenue 0.88 x 2.43 x 2.32 x 2 x 1.62 x 1.82 x 1.63 x
EV / EBITDA -1.87 x -12.2 x -15.2 x -56 x 51.8 x 31.3 x 20.1 x
EV / FCF -1.61 x -4.29 x -8 x -29.1 x 76.4 x -137 x -41.5 x
FCF Yield -62.1% -23.3% -12.5% -3.44% 1.31% -0.73% -2.41%
Price to Book - - - 1.53 x 1.54 x 1.97 x 1.92 x
Nbr of stocks (in thousands) 11,559 70,170 70,170 70,197 70,413 71,235 -
Reference price 2 1.000 0.5400 0.5350 0.5650 0.5200 0.6550 0.6550
Announcement Date 05/06/20 28/04/21 15/03/22 21/03/23 19/03/24 - -
1GBP in Million2GBP
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025
Net sales 1 13.03 12.83 15.12 19.95 23.18 27.11 31.03
EBITDA 1 -6.133 -2.553 -2.302 -0.7131 0.7271 1.576 2.512
EBIT 1 -7.179 -3.315 -3.138 -1.638 -0.3097 0.862 1.736
Operating Margin -55.08% -25.84% -20.75% -8.21% -1.34% 3.18% 5.6%
Earnings before Tax (EBT) 1 -7.66 -10.24 -3.937 -2.305 -1.312 0.0635 0.9785
Net income 1 - -9.709 -3.669 -2.196 -1.347 -0.2325 0.461
Net margin - -75.68% -24.27% -11.01% -5.81% -0.86% 1.49%
EPS 2 -0.6000 -0.2200 -0.0540 -0.0330 -0.0191 -0.001680 0.004180
Free Cash Flow 1 -7.12 -7.251 -4.384 -1.374 0.4929 -0.3585 -1.217
FCF margin -54.63% -56.52% -29% -6.89% 2.13% -1.32% -3.92%
FCF Conversion (EBITDA) - - - - 67.78% - -
FCF Conversion (Net income) - - - - - - -
Dividend per Share - - - - - - -
Announcement Date 05/06/20 28/04/21 15/03/22 21/03/23 19/03/24 - -
1GBP in Million2GBP
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025
Net Debt 1 - - - 0.25 1.05 2.62 3.84
Net Cash position 1 0.09 6.76 2.48 - - - -
Leverage (Debt/EBITDA) - - - -0.3554 x 1.443 x 1.663 x 1.528 x
Free Cash Flow 1 -7.12 -7.25 -4.38 -1.37 0.49 -0.36 -1.22
ROE (net income / shareholders' equity) - - - -8.22% -5.58% 0.1% 2.4%
ROA (Net income/ Total Assets) - - - - - - -
Assets 1 - - - - - - -
Book Value Per Share 2 - - - 0.3700 0.3400 0.3300 0.3400
Cash Flow per Share 2 -0.5700 - - - 0.0100 0 0.0200
Capex 1 0.44 1.37 1.18 0.31 0.32 0.91 2.84
Capex / Sales 3.36% 10.7% 7.82% 1.57% 1.4% 3.34% 9.14%
Announcement Date 05/06/20 28/04/21 15/03/22 21/03/23 19/03/24 - -
1GBP in Million2GBP
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Ratings for Tissue Regenix Group plc

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Medical Software & Technology Services

1st Jan change Capi.
TISSUE REGENIX GROUP PLC Stock Tissue Regenix Group plc
+24.23% 58.9M
VEEVA SYSTEMS INC. Stock Veeva Systems Inc.
-4.29% 29.79B
PRO MEDICUS LIMITED Stock Pro Medicus Limited
+45.89% 9.69B
SECTRA AB Stock Sectra AB
+35.91% 4.5B
EVOLENT HEALTH, INC. Stock Evolent Health, Inc.
-37.06% 2.38B
VERADIGM INC. Stock Veradigm Inc.
-8.01% 1.63B
OMNICELL, INC. Stock Omnicell, Inc.
-30.32% 1.2B
SIMULATIONS PLUS, INC. Stock Simulations Plus, Inc.
+6.59% 953M
LUNIT INC. Stock Lunit Inc.
-41.51% 992M
B-SOFT CO.,LTD. Stock B-SOFT Co.,Ltd.
-45.19% 763M
Medical Software & Technology Services
  1. Stock Market
  2. Equities
  3. TRX Stock
  4. Financials Tissue Regenix Group plc